Dr. Joseph Bass MD, PhD
Kettering Professor & Chief Div of Endocrinology, NORTHWESTERN UNIVERSITY
Member of the Healthcare Council
Council Member Biography
Joseph Bass, MD, PhD, is Kettering Professor and Chief of Endocrinology, Metabolism and Molecular Medicine at Northwestern University. Dr. Bass oversees one of the largest research divisions within the department of medicine at Northwestern University, encompassing both clinical and preclinical programs. He also directs a research program in obesity, diabetes and lipid disease. Dr. Bass has expertise in treatment of obesity, diabetes, hypertension, and hypercholesterolemia. He is on scientific advisory boards for major biotechnology and pharmaceutical companies with a focus on obesity and diabetes drug discovery areas. (This is me - Update Profile)
Employment History
- 2009 - Unspecified
- Kettering Professor & Chief Div of Endocrinology, NORTHWESTERN UNIVERSITY
- 1999 - 2009
- Division Head of Endocrinology and Metabolism, EVANSTON NORTHWESTERN HEALTHCARE
- 1999 - Unspecified
- Associate Professor, NORTHWESTERN UNIVERSITY
- 1993 - 1999
- Instructor of Medicine, THE UNIVERSITY OF CHICAGO
GLG NewsSM Analyses by Joseph Bass
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Another Glinide: Where's the Beef?
March 28, 2008
Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug | www.pipelinereview.com
Elixir has turned to a strategy devoid of innovation by selecting a combination glinide (metiglinide) plus glucophage for treatment of type 2 diabetes. With the new availability of DPP4 inhibitors (sitagliptin/alogliptin) and incretin agonists (eg byetta), what is the prospect of another K channel antagonist. The old problems likely will still appear: hypoglycemia, weight gain, and possibly progression of pancreatic failure/cell death.
-
Warning on A1C Targets and Diabetes Death in ACCORD Trial
February 8, 2008
Hault of ACCORD Study Intensive Treatment Arm | www.nhlbi.nih.gov
Increased death from intensive A1C lowering in diabetic subjects raises new concerns about diabetes therapy, insulin use in combination with oral agents, and clinical biomarkers of disease complications.
-
Predicting Winners in Oral Diabetes Competition: Galvus, Alogliptin & Januvia
February 5, 2008
Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches | www.pipelinereview.com
Oral therapies improve complianceEU approval of Galvus does not erase US doubts
-
Alogliptin on the diabetes horizon.
January 9, 2008
Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | www.pipelinereview.com
Diabetes is on the rise globallyExisting oral therapeutics have significant drawbacks but are cheap (generic) and some have been in use for many years.
GLG Study Groups with Joseph Bass(?)
| Study Group Name | No. Members |
|---|---|
| Physicians who Treat Hypertension (US) | 949 |
| Physicians who Treat Diabetes (US) | 638 |
| Endocrinologists (US) | 628 |
| Byetta Prescribers for Diabetes | 295 |
| Physicians who Treat Hypercholesterolemia in the U.S. | 293 |
GLG Live Meetings with Joseph Bass(?)
Joseph Bass has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.